Canine Insulinoma Study Guide

Overview and Clinical Importance

Insulinomas are the most common endocrine tumors of the canine pancreas, arising from the beta cells of the islets of Langerhans. These functional neuroendocrine tumors inappropriately secrete excessive insulin, leading to profound and potentially life-threatening hypoglycemia. Understanding insulinomas is critical for the NAVLE as they represent an important intersection of endocrinology, oncology, and emergency medicine.

Unlike human insulinomas, which are benign in approximately 90% of cases, canine insulinomas are malignant in greater than 95% of cases and frequently metastasize to regional lymph nodes and the liver. Approximately 45-55% of dogs have metastatic disease at the time of diagnosis, making early detection and appropriate staging crucial for treatment planning and prognosis.

Signalment and Epidemiology

Breed Predisposition

While any breed can be affected, large and medium-sized breeds are overrepresented. Commonly affected breeds include German Shepherds, Irish Setters, Boxers, Golden Retrievers, Labrador Retrievers, Standard Poodles, and various terrier breeds. Recent reports also document insulinomas in smaller breeds including West Highland White Terriers, Chihuahuas, Yorkshire Terriers, and French Bulldogs.

Age and Sex

Insulinomas typically affect middle-aged to older dogs, with a mean age at diagnosis of approximately 9 years (range: 3-15 years). Unlike in humans where females are more commonly affected, there is no sex predilection in dogs. Younger dogs that develop insulinoma may have a worse prognosis compared to older dogs.

Pathophysiology

Normal Glucose Regulation

In normal dogs, glucose homeostasis is maintained through intricate interactions between the endocrine system, autonomic nervous system, and liver. The beta cells of the pancreatic islets of Langerhans comprise approximately 60-75% of islet cell mass and are responsible for insulin secretion in response to rising blood glucose levels. Insulin secretion is tightly regulated by a negative feedback mechanism: as blood glucose falls, insulin secretion is inhibited.

Insulinoma Pathophysiology

In dogs with insulinoma, neoplastic beta cells continue to secrete insulin despite hypoglycemia because the normal negative feedback mechanism is disrupted. Recent research suggests that overexpression of glucokinase (GCK) in insulinoma cells may partially explain this autonomous insulin secretion. The resulting hyperinsulinemia causes:

• Suppression of hepatic glucose secretion by inhibiting glycogenolysis and gluconeogenesis
• Increased glucose uptake by muscle and adipose tissue
• Progressive hypoglycemia leading to neuroglycopenia (glucose deprivation to the brain)

Clinical Signs

Whipple's Triad

Whipple's triad is a classic clinical finding that suggests hypoglycemia and should raise suspicion for insulinoma. The triad consists of:

• Clinical signs of hypoglycemia (neurologic signs, weakness, collapse)
• Documented low blood glucose (less than 50 mg/dL or less than 2.8 mmol/L)
• Resolution of clinical signs following glucose administration or feeding

Neuroglycopenic Signs

The brain is an obligate glucose consumer with limited glycogen stores and limited ability to use alternative energy sources. Neuroglycopenic signs result from glucose deprivation to the central nervous system:

• Weakness, lethargy, and exercise intolerance
• Ataxia and incoordination
• Mental confusion, disorientation, and behavioral changes
• Apparent blindness
• Seizures (focal or generalized)
• Stupor, coma, and death in severe cases

Counter-Regulatory Signs

Hypoglycemia triggers release of counter-regulatory hormones (glucagon, catecholamines, cortisol, growth hormone). The resulting adrenergic signs include:

• Trembling and muscle fasciculations
• Restlessness and anxiety
• Tachycardia and palpitations
• Polyphagia

Pattern of Clinical Signs

Clinical signs are typically episodic and intermittent, often triggered by:

• Fasting - prolonged periods without food
• Exercise - increased muscle glucose uptake
• Excitement - catecholamine release can paradoxically worsen signs
• Feeding - paradoxically, eating can trigger insulin release from the tumor

Owners commonly report that their dog seems "spacy," "lost," or "not themselves" during episodes. Early signs are often vague and may be dismissed until severity increases. Importantly, the degree of neurologic impairment does not directly correlate with specific blood glucose levels; some dogs tolerate remarkably low glucose levels while others become symptomatic at higher levels, depending on the chronicity of hypoglycemia and individual adaptation.

Physical Examination Findings

Physical examination is often unremarkable between hypoglycemic episodes. Notable findings may include:

• Increased body condition score due to anabolic effects of insulin
• Post-ictal changes if seizure activity recently occurred
• Peripheral polyneuropathy (paraneoplastic) - pelvic limb paresis or tetraparesis with decreased reflexes

Diagnosis

Diagnostic Approach

The diagnosis of insulinoma requires demonstration of the simultaneous occurrence of hypoglycemia and inappropriately normal or elevated insulin levels. No single test provides definitive diagnosis; histopathology remains the gold standard for confirmation.

Laboratory Findings

Blood Glucose

Fasting hypoglycemia (blood glucose less than 60 mg/dL or less than 3.3 mmol/L) is the hallmark finding. Most dogs with insulinoma develop hypoglycemia within 24 hours when food is withheld. However, a normal blood glucose does NOT rule out insulinoma, as dogs may be normoglycemic at presentation due to counter-regulatory hormone secretion.

Key Diagnostic Values

Exam Focus: The KEY diagnostic principle is demonstrating inappropriately elevated or normal insulin levels in the face of hypoglycemia. ALWAYS draw a blood sample for insulin measurement BEFORE administering dextrose in a hypoglycemic patient - you may not get another opportunity!

Differential Diagnosis of Hypoglycemia

Diagnostic Imaging

Abdominal Ultrasound

Abdominal ultrasound is widely available but has limited sensitivity (approximately 36-56%) for detecting primary insulinomas. Insulinomas are typically small (less than 2.5 cm diameter) and may appear as hypoechoic or isoechoic nodules within the pancreatic parenchyma. Ultrasound cannot reliably detect lymph node metastases. However, ultrasound is valuable for:

• Guiding fine-needle aspiration (FNA) of hepatic lesions
• Ruling out other causes of hypoglycemia (hepatic disease, other tumors)
• Initial screening when CT is not available

Computed Tomography (CT)

Contrast-enhanced CT is the gold standard imaging modality for insulinoma detection and staging. Dual-phase or triple-phase CT angiography provides sensitivity of approximately 71% for detecting pancreatic masses. Insulinomas typically appear as hypervascular lesions showing arterial enhancement. CT is essential for:

• Tumor localization within the pancreas
• Detection of lymph node metastases
• Assessment of hepatic metastases
• Surgical planning
• TNM staging

Imaging Modality Comparison

TNM Staging System

Canine insulinomas are staged according to the WHO's TNM (Tumor-Node-Metastasis) system. Staging is a critical prognostic factor and guides treatment decisions.

Treatment

Emergency Management of Hypoglycemic Crisis

The immediate goal is to control clinical signs, NOT to normalize blood glucose. Excessive dextrose administration can stimulate further insulin release from the tumor, causing rebound hypoglycemia.

Home Emergency Protocol

Instruct owners to rub corn syrup or sugar solution on the buccal mucosa. Once the dog can swallow, offer a small meal and seek veterinary attention immediately.

Hospital Emergency Protocol

• Draw blood for insulin measurement BEFORE administering dextrose
• Administer 50% dextrose (0.5-1 mL/kg) diluted 1:4 with saline, given slowly IV over 5-10 minutes
• Start dextrose CRI (2.5-5% dextrose in fluids) to maintain blood glucose
• If seizures persist after glucose normalization, administer benzodiazepines (diazepam 0.5-1 mg/kg IV)
• Monitor blood glucose frequently and adjust dextrose infusion rate

Surgical Treatment

Surgery is the treatment of choice for insulinoma and provides the best survival times. Even in patients with metastatic disease, surgical debulking reduces insulin-secreting tissue and can improve quality of life.

Surgical Procedures

• Partial pancreatectomy - preferred procedure for solitary masses
• Tumor enucleation - for small, well-encapsulated tumors
• Metastatic lesion resection - debulking of hepatic and lymph node metastases

Perioperative Considerations

Perioperative management is critical. Continuous blood glucose monitoring is essential as manipulation of the tumor can cause massive insulin release. A dextrose-containing fluid (2.5-5%) should be administered throughout surgery. Low-dose dexmedetomidine (1 mcg/kg) may help inhibit insulin release during anesthesia.

Postoperative Complications

• Pancreatitis - most common complication
• Transient hyperglycemia/diabetes mellitus - body has downregulated insulin production
• Persistent hypoglycemia - indicates residual tumor/microscopic disease
• Neurologic complications - from chronic neuroglycopenia

Medical Treatment

Medical management is indicated when surgery is declined, contraindicated due to extensive metastasis, or when hypoglycemia recurs postoperatively.

Dietary Management

• Feed 4-6 small meals daily
• Diet should be high in protein, fat, and complex carbohydrates
• Avoid simple sugars - cause rapid insulin release
• Restrict exercise to short leash walks only

Medical Therapy Options

Prognosis and Survival

Prognosis for canine insulinoma is guarded to poor due to the high rate of malignancy (greater than 95%). Clinical hypoglycemia almost always recurs due to tumor regrowth or metastasis. However, appropriate treatment can provide significant quality time.

Survival Times by Treatment Approach

Prognostic Factors

• TNM stage - most important prognostic factor
• Postoperative glucose status - normoglycemic/hyperglycemic dogs have better prognosis than persistently hypoglycemic dogs
• Age - younger dogs may have worse prognosis
• Ki67 index - higher proliferation markers indicate worse prognosis
• Tumor size - larger tumors correlate with poorer outcomes